Global CNS Disorders Drug Market Expected To Grow At A CAGR Of 7.72% Over 2016-2020

Date: 2016-09-19

The Central Nervous System Diseases are universal diseases among the aged people, along the growing aged population around the world, Global CNS Disorders Drug market is expected to grow at a CAGR of 7.72% over 2016-2020.

On the basis of geography, the Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS application market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer’s markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer’s Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

In Asia, China and Japan are facing the aged population is fostering the growth of CNS Disorders Drug market, which is expected to be fast growing regions across the world.

CNS Disorders Drug market share by region as following:


Read Full Report:

Joanna | Executive – International Business and partner Relations
E-mail: | Tel: 510-400-8520


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample